Description
Estrone-3-glucuronide is the predominant metabolite of estradiol in urine and a urinary marker for the fertile window in women. Measurement of urinary glucuronides is a convenient, non-invasive method for detecting reproductive hormone levels compared to measuring plasma levels. Estrone-3-glucuronide, along with pregnanediol-3-glucuronide, are indicators of female reproductive health. Literature has shown high serum estrone levels, which directly correlate to urinary estrone-3-glucuronide levels, are associated with estrogen receptor-positive breast cancers. Hormone receptor status is the main factor in planning treatment and can be treated with hormone therapies, including tamoxifen and aromatase inhibitors. In addition to its role in breast cancer, circulating estrogens, including estrone metabolized from oral hormone replacement therapy, have been shown to increase thrombin generation leading to higher risk for blood clots, myocardial infarctions, deep vein thrombosis and strokes.
References
[1] SAMANTHA F EICHNER Erin M T. Urinary-based ovulation and pregnancy: point-of-care testing.[J]. Annals of Pharmacotherapy, 2004, 38 2: 325-331. DOI:
10.1345/aph.1d210[2] YASUO MIYOSHI. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.[J]. Clinical Cancer Research, 2003, 9 6: 2229-2233.
[3] C. N. BAGOT. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy[J]. Journal of Thrombosis and Haemostasis, 2010, 8 8: 1736-1744. DOI:
10.1111/j.1538-7836.2010.03953.x[4] ROKSANA KARIM. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women.[J]. Journal of Clinical Endocrinology & Metabolism, 2009, 94 11: 4136-4143. DOI:
10.1210/jc.2009-0643[5] M.D. M D, PH.D. NAN M M D, PH.D. FAXIN R M D, et al. Prospective Study of Effects of Endogenous Estrogens on Myocardial No-Reflow Risk in Postmenopausal Women with Acute Myocardial Infarction[J]. Journal of interventional cardiology, 2014, 27 5: 437-443. DOI:
10.1111/joic.12137
